

## Regulatory Story

[Go to market news section](#)



**Company** [Omega Diagnostics Group PLC](#)  
**TIDM** ODX  
**Headline** Exclusive Licence Agreement  
**Released** 07:35 28-Mar-2011  
**Number** 7117D07



RNS Number : 7117D  
Omega Diagnostics Group PLC  
28 March 2011

### **OMEGA DIAGNOSTICS GROUP PLC ("OMEGA DIAGNOSTICS" OR THE "COMPANY")**

#### **Exclusive Licence Agreement and Omega Diagnostics GmbH update**

##### **Exclusive Licence Agreement**

Omega Diagnostics, the AIM-listed medical diagnostics company, announces that it has signed an agreement with Immunodiagnostic Systems France SA (a subsidiary of Immunodiagnostic Systems Holdings plc) ("IDS") for the exclusive worldwide rights to develop and distribute allergy tests on its US FDA-cleared IDS-iSYS automated instrument. IDS will supply instruments and other consumables necessary to enable Omega to develop and distribute allergy tests. Omega has the right to co-brand the closed system IDS-iSYS instrument for allergy testing with its Allersys™ brand image.

The signing of this agreement is a key strategic milestone following on from the acquisition of the IVD Business of Allergopharma last year. It will enable the Group to progress with its strategy to develop allergy-based products on an automated closed system platform that will be able to process much higher volumes of tests than the current 'open system' platform acquired with the IVD Business. It is expected that the product development programme which will be funded from proceeds raised from the Placing last November will take around one year to complete, after which it is intended that the new allergy test kit/instrument product offering will be launched through Omega's international distribution network, which should result in a substantial increase in the scale of the Group.

The Directors believe that this represents a significant opportunity for Omega Diagnostics giving it improved access to the worldwide market for in-vitro allergy testing products.

##### **Omega Diagnostics GMBH**

The Company is pleased to report that the IVD Business has performed in line with management's expectations since acquisition and unaudited turnover in the first two full months of ownership in this division has shown a like-for-like increase of approximately 7% over the same period in the previous year.

##### **For further information please contact:**

**Omega Diagnostics Group  
PLC**

Tel: 01259 763 030

Andrew Shepherd, Chief  
Executive  
Kieron Harbinson, Group Finance  
Director

[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**Cenkos Securities  
plc**  
Ian Soanes  
Elizabeth Bowman

Tel: 020 7397 8900

**Walbrook PR Limited**  
Paul McManus

Tel: 020 7933 8787  
Mob: 07980 541 893

[Paul.mcmanus@walbrookpr.com](mailto:Paul.mcmanus@walbrookpr.com)

Paul Cornelius

Tel: 020 7933 8794  
Mob: 07866 384 707

[paul.cornelius@walbrookir.com](mailto:paul.cornelius@walbrookir.com)

This information is provided by RNS  
The company news service from the London Stock Exchange

END

AGRFMGZFVRDGMZG

CLOSE

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

©2009 London Stock Exchange plc. All rights reserved

Regulatory